Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q2 2018 · 10-Q
Revenue$71.04M$71.04M+9.0% vs Q2 2017 Net Income-$2.85M-$2.85MN/M vs Q2 2017 EPS Diluted-$0.06-$0.06N/M vs Q2 2017 Gross Profit$26,064,000−2.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flowderived$4,533,000−0.9% Free Cash Flowderived-$7,718,000N/M Margins · derivedGross margin36.7%−4.2 pt vs Q2 2017
Operating margin-4.1%−7.5 pt vs Q2 2017
Net margin-4.0%−7.0 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 9, 2018 · 40 d after period end